1.64
前日終値:
$1.68
開ける:
$1.69
24時間の取引高:
1.57M
Relative Volume:
1.15
時価総額:
$97.89M
収益:
-
当期純損益:
$-144.01M
株価収益率:
-0.409
EPS:
-4.01
ネットキャッシュフロー:
$-113.02M
1週間 パフォーマンス:
-38.39%
1か月 パフォーマンス:
-14.77%
6か月 パフォーマンス:
-6.00%
1年 パフォーマンス:
-84.74%
Biomea Fusion Inc Stock (BMEA) Company Profile
BMEA を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
BMEA
Biomea Fusion Inc
|
1.645 | 118.78M | 0 | -144.01M | -113.02M | -4.01 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
408.60 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
472.79 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
562.45 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
801.26 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
331.07 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-08-28 | 開始されました | Jefferies | Buy |
2025-06-03 | 再開されました | Piper Sandler | Overweight |
2024-10-09 | 開始されました | Edward Jones | Buy |
2024-09-27 | アップグレード | Rodman & Renshaw | Neutral → Buy |
2024-09-27 | アップグレード | Truist | Hold → Buy |
2024-08-29 | 開始されました | CapitalOne | Overweight |
2024-06-11 | ダウングレード | Truist | Buy → Hold |
2024-06-07 | ダウングレード | Barclays | Overweight → Equal Weight |
2024-04-02 | ダウングレード | JP Morgan | Overweight → Neutral |
2024-02-06 | 開始されました | Truist | Buy |
2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
2023-06-26 | ダウングレード | Jefferies | Buy → Hold |
2023-05-12 | 開始されました | Barclays | Overweight |
2023-03-29 | 繰り返されました | Oppenheimer | Outperform |
2023-03-28 | 繰り返されました | H.C. Wainwright | Buy |
2023-02-24 | 開始されました | Citigroup | Buy |
2022-06-02 | 再開されました | H.C. Wainwright | Buy |
2022-01-12 | 開始されました | H.C. Wainwright | Buy |
2021-12-17 | 開始されました | Oppenheimer | Outperform |
2021-05-11 | 開始されました | JP Morgan | Overweight |
2021-05-11 | 開始されました | Jefferies | Buy |
2021-05-11 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Biomea Fusion Inc (BMEA) 最新ニュース
Real time pattern detection on Biomea Fusion Inc. stockWeekly Trade Analysis & Free Risk Controlled Daily Trade Plans - newser.com
Is Biomea Fusion Inc. meeting your algorithmic filter criteriaJuly 2025 Momentum & AI Powered Buy and Sell Recommendations - newser.com
Biomea Fusion Inc. stock retracement – recovery analysisWeekly Trading Summary & Safe Entry Momentum Stock Tips - newser.com
Should you wait for a breakout in Biomea Fusion Inc.Portfolio Value Summary & Fast Exit and Entry Strategy Plans - newser.com
Biomea Fusion (NASDAQ:BMEA) Trading Up 6.5%What's Next? - MarketBeat
Tools to assess Biomea Fusion Inc.’s risk profileMarket Sentiment Review & Technical Entry and Exit Alerts - newser.com
Biomea Fusion (NASDAQ:BMEA) Given "Sell (E+)" Rating at Weiss Ratings - MarketBeat
Does Biomea Fusion Inc. fit your quant trading model2025 Market Overview & Precise Swing Trade Entry Alerts - newser.com
What analysts say about Biomea Fusion Inc stockBollinger Bands Signals & Free Unmatched Market Gains - earlytimes.in
Why Biomea Fusion (BMEA) Is Up After Positive Diabetes Data and $25M Equity Raise – And What’s Next - Yahoo Finance
Biomea Fusion Announces Positive Phase II Study Results - MSN
Why Biomea Fusion (BMEA) Is Up on Promising Phase II Diabetes Data and What It Could Mean Next - simplywall.st
Nasdaq Tumbles 200 Points; Trilogy Metals Shares Spike Higher - Benzinga
Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups - insights.citeline.com
Biomea’s ‘durable’ menin inhibitor advancing in hard-to-treat diabetes - BioWorld MedTech
Biomea Fusion: Surging On Data, Sinking On FundingI'm On The Sidelines - Seeking Alpha
Traders Purchase High Volume of Biomea Fusion Call Options (NASDAQ:BMEA) - MarketBeat
Biomea Fusion Stock Plummets Following Public Offering, Diabetes Study - inkl
Dow Jumps Over 100 Points; McCormick Earnings Top Views - Benzinga
Biomea Fusion announces pricing of public offering of securities - MSN
Biomea Fusion prices $25 million public offering of shares and warrants - Investing.com
Biomea Fusion plunges on $25 mln stock-and-warrants offering - TradingView
Biomea Fusion Announces Pricing of Public Offering of Securities - The Manila Times
D. Boral Capital Maintains Biomea Fusion (BMEA) Buy Recommendation - Nasdaq
$25M Offering: Biomea Fusion Prices 11.2M Shares & Warrants at $2.05 — Closing Oct 8, 2025 - Stock Titan
Biomea Fusion announces proposed public offering of securities - MarketScreener
Biomea Fusion, Inc. (BMEA) Stock: Volatile Surge Ahead of Jefferies-Led Equity Offering - parameter.io
Biomea's diabetes drug shows promise, may work for those not responding to GLP-1 - MarketScreener
Biomea announces positive 52-week results from phase II COVALENT-111 study in type 2 diabetes - MarketScreener
Biomea Fusion Reports Phase 2 Data in Diabetes, Launches Stock Offering - MarketScreener
Biomea Fusion Announces Proposed Public Offering of Securities - GlobeNewswire
Biomea Fusion launches public offering of common stock and warrants By Investing.com - Investing.com Australia
Biomea Fusion launches public offering of common stock and warrants - Investing.com India
Biomea Fusion reports 52-week results from Phase II diabetes trial - Investing.com
Biomea Fusion Reports Positive 52-Week Results from Phase II COVALENT-111 Study of Icovamenib in Type 2 Diabetes Patients - Quiver Quantitative
1.8% HbA1c reduction sustained at Week 52 — Biomea Fusion's icovamenib shows durable benefit - Stock Titan
Why Biomea Fusion Inc. stock remains undervaluedTrade Risk Summary & Safe Entry Zone Identification - newser.com
Visualizing Biomea Fusion Inc. stock with heatmapsVolume Spike & Weekly High Potential Alerts - newser.com
Biomea Fusion (NASDAQ:BMEA) Receives “Buy” Rating from D. Boral Capital - Defense World
BMEA: D. Boral Capital Maintains Buy Rating with $16 PT | BMEA S - GuruFocus
Biomea Fusion's (BMEA) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
How geopolitical tensions affect Biomea Fusion Inc. stockShort Setup & Smart Money Movement Alerts - newser.com
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Biomea Fusion, Inc. reports inducement grant under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
48,000 Stock Options: Biomea Fusion Makes Key Inducement Grant Under 2023 Equity Plan - Stock Titan
What drives Biomea Fusion Inc stock priceExit Strategy Tips & Affordable Growth Investments - earlytimes.in
Biomea Fusion appoints Mick Hitchcock to succeed Thomas Butler as interim CEO - MSN
What Forward P E Multiple Suggests About Pritish Nandy Communications Ltds ValuationMarket Insider Reports & Low Entry Cost Investments - earlytimes.in
Biomea Fusion Inc (BMEA) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):